Aquestive Therapeutics (NASDAQ:AQST) Stock Price Up 6.5% – Should You Buy?

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) rose 6.5% during trading on Monday . The stock traded as high as $5.82 and last traded at $5.74. Approximately 670,326 shares traded hands during trading, a decline of 66% from the average daily volume of 1,995,991 shares. The stock had previously closed at $5.39.

Analyst Ratings Changes

A number of research firms have recently commented on AQST. Lifesci Capital upgraded shares of Aquestive Therapeutics to a “strong-buy” rating in a report on Wednesday, September 3rd. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Zacks Research raised Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th. Citigroup restated an “outperform” rating on shares of Aquestive Therapeutics in a research note on Thursday, October 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $10.00.

Aquestive Therapeutics Stock Up 4.6%

The company has a market cap of $742.98 million, a P/E ratio of -8.37 and a beta of 1.79. The business’s 50 day moving average is $6.03 and its 200 day moving average is $4.42.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The business had revenue of $12.81 million for the quarter, compared to analyst estimates of $12.94 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Insider Transactions at Aquestive Therapeutics

In related news, insider Carl N. Kraus sold 20,272 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $7.00, for a total transaction of $141,904.00. Following the sale, the insider directly owned 282,475 shares of the company’s stock, valued at $1,977,325. This trade represents a 6.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Peter E. Boyd sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $5.30, for a total transaction of $79,500.00. Following the sale, the insider directly owned 288,323 shares in the company, valued at $1,528,111.90. The trade was a 4.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 276,770 shares of company stock valued at $1,692,203 over the last three months. Company insiders own 7.85% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AQST. Victory Capital Management Inc. lifted its stake in Aquestive Therapeutics by 17.0% in the 3rd quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock valued at $72,000 after buying an additional 1,862 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Aquestive Therapeutics by 6.0% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock valued at $156,000 after purchasing an additional 2,649 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after purchasing an additional 4,134 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Aquestive Therapeutics by 16.6% during the second quarter. The Manufacturers Life Insurance Company now owns 32,073 shares of the company’s stock worth $106,000 after buying an additional 4,557 shares in the last quarter. Finally, Bank of Montreal Can raised its position in shares of Aquestive Therapeutics by 31.1% in the second quarter. Bank of Montreal Can now owns 20,052 shares of the company’s stock valued at $66,000 after buying an additional 4,752 shares during the last quarter. Hedge funds and other institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.